The estimated Net Worth of Brian Achenbach is at least $524 mil dollars as of 8 December 2021. Mr. Achenbach owns over 4,374 units of Mustang Bio Inc stock worth over $38,411 and over the last 7 years he sold MBIO stock worth over $84,458. In addition, he makes $400,712 as Senior Vice President - Finance e Corporate Controller at Mustang Bio Inc.
Sign up
Mr. Achenbach MBIO stock SEC Form 4 insiders trading
Brian has made over 4 trades of the Mustang Bio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 4,374 units of MBIO stock worth $8,004 on 8 December 2021.
The largest trade he's ever made was selling 20,721 units of Mustang Bio Inc stock on 6 December 2019 worth over $66,307. On average, Brian trades about 4,578 units every 201 days since 2018. As of 8 December 2021 he still owns at least 144,729 units of Mustang Bio Inc stock.
You can see the complete history of Mr. Achenbach stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Brian Achenbach biography
Brian Achenbach serves as Senior Vice President - Finance, Corporate Controller of the Company. He joined Mustang in October 2017 as Vice President of Finance & Corporate Controller. Prior to Mustang, Mr. Achenbach served as Vice President & Corporate Controller at Amerigen Pharmaceuticals Limited, where he oversaw finance and accounting functions as the company established itself as a commercial organization in the U.S. and China. Prior to Amerigen, Mr. Achenbach served as Vice President of Finance for the Americas and Vice President of Global Financial Planning & Analysis at ConvaTec Group PLC, a global medical products and technologies company, where he led finance and accounting operations in the U.S., Canada and South America. Earlier in his career, Mr. Achenbach held roles of increasing responsibility in finance and accounting at Mylan N.V., Andrx Corporation (acquired by Watson Pharmaceuticals Inc. in 2006) and IVAX Corporation (acquired by Teva Pharmaceutical Industries Ltd. in 2005). Mr. Achenbach holds an M.B.A. in finance from Roosevelt University in Chicago, and a B.A. in economics from the University of Florida in Gainesville.
What is the salary of Brian Achenbach?
As the Senior Vice President - Finance e Corporate Controller of Mustang Bio Inc, the total compensation of Brian Achenbach at Mustang Bio Inc is $400,712. There are 2 executives at Mustang Bio Inc getting paid more, with Dr. Manuel Litchman having the highest compensation of $606,871.
How old is Brian Achenbach?
Brian Achenbach is 55, he's been the Senior Vice President - Finance e Corporate Controller of Mustang Bio Inc since 2019. There are 6 older and 2 younger executives at Mustang Bio Inc. The oldest executive at Mustang Bio Inc is Dr. Manuel Litchman, 67, who is the Pres, CEO & Director.
Insiders trading at Mustang Bio Inc
Over the last 7 years, insiders at Mustang Bio Inc have traded over $122,072 worth of Mustang Bio Inc stock and bought 951,208 units worth $2,853,591 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss, eManuel Md Litchman. On average, Mustang Bio Inc executives and independent directors trade stock every 89 days with the average trade being worth of $15,504. The most recent stock trade was executed by Manuel Md Litchman on 18 March 2022, trading 10,000 units of MBIO stock currently worth $6,300.
What does Mustang Bio Inc do?
mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.
What does Mustang Bio Inc's logo look like?
Complete history of Mr. Achenbach stock trades at Mustang Bio Inc
Mustang Bio Inc executives and stock owners
Mustang Bio Inc executives and other stock owners filed with the SEC include:
-
Dr. Manuel Litchman,
Pres, CEO & Director -
Manuel Litchman,
President, Chief Executive Officer, Director -
Brian Achenbach,
Senior Vice President - Finance, Corporate Controller -
Brian K. Achenbach M.B.A.,
Sr. VP of Fin. & Corp. Controller -
Adam Chill,
Independent Director -
Michael Weiss,
Executive Chairman of the Board -
Michael Zelefsky,
Independent Director -
Neil Herskowitz,
Independent Director -
Lindsay Rosenwald,
Director -
Michael S. Weiss Esq.,
Exec. Chairman -
Robyn M. Hunter,
Corp. Sec. -
Dr. Bruce Dezube M.D.,
Sr. VP & Head of Clinical Devel. -
Scott Smith M.B.A.,
Exec. Director and Head of Alliance & Program Management -
Lynn E. Bayless,
Head of Regulatory Affairs -
Debra Manning SPHR,
VP of HR -
Matthew Wein J.D.,
VP & Gen. Counsel -
Dr. Knut Niss,
Chief Technology Officer -
Biotech, Inc. Fortress,
10% owner